NASDAQ$VERU
Veru Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Veru reported fiscal Q2 2025 with a net loss of $7.9M and diluted EPS of $0.05, with no commercial revenue from continuing operations.
For the quarter ended March 31, 2025, Veru posted a net loss of $7.9 million ($0.05 per diluted share) versus a $10.0 million loss a year ago. Continuing operations had no product revenue; operating expenses were $9.1 million, led by $3.9 million of R&D and $5.2 million of SG&A. The company closed the FC2 female condom divestiture in December 2024, recognized a $1.0 million gain on ENTADFI asset sales, and ended the quarter with $20.0 million in cash and cash equivalents.
- Net loss $7.9M; diluted EPS ($0.05) improved from ($0.07) in the prior-year quarter.
- No commercial revenue from continuing operations; R&D spend rose to $3.9M (+32% YoY).
- FC2 business sale generated $16.3M net divestiture proceeds in the six months ended March 31, 2025.
- Cash and cash equivalents were $20.0M at quarter end; six-month operating cash use was $19.1M.
- Pipeline focus on enobosarm (GLP-1 RA muscle-loss adjunct) and sabizabulin (cardiovascular outcomes).
Headline financials
Revenue & EPS history
Veru · Revenue · Quarterly
$0
Forward guidance
Management highlights clinical and regulatory milestones for enobosarm and sabizabulin rather than near-term product revenue. The 10-Q cites risks around trial timing, FDA interactions, financing needs, and the post-FC2 royalty structure.
Tailwinds
- Enobosarm development targets GLP-1 RA patients at risk of muscle loss—a large unmet need.
- FC2 divestiture proceeds and ENTADFI monetization bolster liquidity.
- Net loss narrowed versus the prior-year fiscal Q2 quarter.
Headwinds
- No commercial revenue; ongoing operating cash burn near $19M in the first half of fiscal 2025.
- Clinical, regulatory, and financing risks could delay or prevent approval.
- Residual FC2 royalty obligations and discontinued-ops wind-down costs remain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
+1.5%
Avg return
Earnings day
+8.3%
Avg return
5 days after
+9.6%
Avg return
30 days after
45%
30 / 66 earnings
Positive
+83.7%
Q4 2020
Best reaction
-23.5%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.8% | -6.7% | +33.8% | |
| Q1 2026 | -0.4% | -0.9% | +3.5% | |
| Q4 2025 | -8.4% | -6.1% | +10.2% | |
| Q3 2025 | -12.0% | +0.0% | -0.8% | |
| Q2 2025 | +4.1% | +4.0% | +24.0% | |
| Q1 2025 | -4.5% | +0.0% | -12.7% | |
| Q4 2024 | -1.3% | -9.7% | +2.8% | |
| Q3 2024 | +7.1% | +6.5% | +10.4% | |
| Q4 2023 | +3.5% | +11.8% | -4.7% | |
| Q2 2024 | -16.0% | -18.4% | -43.6% | |
| Q1 2024 | -13.7% | -13.6% | +47.7% | |
| Q3 2023 | +5.6% | +3.7% | -4.6% | |
| Q2 2023 | -23.5% | -27.5% | -12.1% | |
| Q1 2023 | -19.1% | -21.8% | -57.5% | |
| Q4 2022 | +2.9% | -0.5% | -1.3% | |
| Q3 2022 | +62.1% | +89.0% | +32.3% | |
| Q2 2022 | +59.3% | +91.2% | +60.8% | |
| Q1 2022 | +9.4% | +7.4% | -8.8% | |
| Q4 2021 | -12.3% | -8.1% | -14.8% | |
| Q3 2021 | +8.8% | -2.0% | +31.3% | |
| Q2 2021 | -3.2% | +3.7% | +18.7% | |
| Q1 2021 | -2.3% | +7.8% | -22.3% | |
| Q4 2020 | +83.7% | +198.5% | +193.8% | |
| Q3 2020 | -11.6% | -10.9% | -9.9% | |
| Q2 2020 | +13.9% | +10.5% | -5.4% | |
| Q1 2020 | +0.9% | -0.9% | -29.8% | |
| Q4 2019 | -1.6% | +17.1% | +64.5% | |
| Q3 2019 | -14.0% | -11.0% | -16.2% | |
| Q2 2019 | -4.8% | -1.8% | +20.8% | |
| Q1 2019 | -8.1% | -10.7% | +0.0% | |
| Q4 2018 | -4.9% | +0.7% | -1.4% | |
| Q3 2018 | +1.0% | +1.0% | -13.6% | |
| Q2 2018 | -1.2% | +6.6% | +18.7% | |
| Q1 2018 | +0.8% | +2.3% | +50.4% | |
| Q4 2017 | +28.9% | +29.8% | +10.5% | |
| Q3 2017 | -11.3% | -4.0% | +2.0% | |
| Q2 2017 | -1.0% | -2.9% | +17.6% | |
| Q1 2017 | +1.9% | +3.8% | -1.9% | |
| Q4 2016 | -6.2% | -8.8% | -10.6% | |
| Q3 2016 | -2.3% | +1.6% | +2.3% | |
| Q2 2016 | -12.3% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +9.9% | — | — | |
| Q2 2015 | -8.1% | — | — | |
| Q1 2015 | +2.9% | — | — | |
| Q4 2014 | -8.5% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | -3.7% | — | — | |
| Q1 2014 | -4.1% | — | — | |
| Q4 2013 | +3.4% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +5.8% | — | — | |
| Q1 2013 | -4.2% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +4.7% | — | — | |
| Q2 2012 | -9.2% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q1 2012 | +4.7% | — | — | |
| Q4 2009 | +5.5% | — | — | |
| Q4 2011 | +5.5% | — | — | |
| Q2 2011 | +5.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | -5.4% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2010 | +0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro